Published in J Gastrointest Cancer on June 01, 2015
Spontaneous regression of hepatocellular carcinoma: A mini-review. World J Gastroenterol (2017) 0.75
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol (2008) 23.93
Hepatocellular carcinoma. Lancet (2003) 22.54
Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 8.46
Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet (2000) 4.60
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol (2013) 2.63
Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. J Hepatol (2006) 1.69
Spontaneous regression of hepatocellular carcinoma: three case reports and a categorized review of the literature. Dig Dis Sci (2008) 1.08
Potential of immunotherapy for hepatocellular carcinoma. J Hepatol (2010) 1.06
Melanoma as a model tumour for immuno-oncology. Ann Oncol (2012) 0.95
Vanishing liver tumours. Clin Radiol (2007) 0.83
Regression of a renal cell carcinoma following allogeneic peripheral blood stem cell transplant for acute myeloid leukaemia: evidence of a graft-versus-tumour effect without significant graft-versus-host disease. Br J Haematol (2012) 0.81
Temporary spontaneous regression of intrahepatic cholangiocarcinoma. Comput Med Imaging Graph (1997) 0.80
Genetic and pharmacological factors that influence reproductive aging in nematodes. PLoS Genet (2006) 1.70
Pharmacology of delayed aging and extended lifespan of Caenorhabditis elegans. Exp Gerontol (2006) 1.07
Regulation of intrahepatic biliary duct morphogenesis by Claudin 15-like b. Dev Biol (2011) 1.02
Multidisciplinary management of hepatocellular carcinoma. Clin Gastroenterol Hepatol (2011) 0.98
The anticonvulsant ethosuximide disrupts sensory function to extend C. elegans lifespan. PLoS Genet (2008) 0.90
Nonadherence to imatinib during an economic downturn. N Engl J Med (2010) 0.86
Focal Nodular Hyperplasia and Hepatocellular Adenoma around the World Viewed through the Scope of the Immunopathological Classification. Int J Hepatol (2013) 0.86
Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model. Int J Cancer (2014) 0.83
Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas. Am J Clin Oncol (2012) 0.82
Effects of anticonvulsant drugs on life span. Arch Neurol (2006) 0.80
KRAS mutational analysis for colorectal cancer. Application: pharmacogenomic. PLoS Curr (2010) 0.79
Can we cure cholangiocarcinoma with neoadjuvant chemoradiation and liver transplantation? Time for a multicenter trial. Liver Transpl (2012) 0.78
Salvage liver transplantation for recurrent hepatocellular carcinoma after radiofrequency ablation: a new strategy? J Hepatol (2011) 0.77
90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot study. J Gastrointest Cancer (2014) 0.76
A 46-Year-Old Asian Woman With Liver Mass. Semin Oncol (2015) 0.75